Platelet glycogenolysis is important for energy production and function
Open Access
- 9 June 2023
- journal article
- research article
- Published by Taylor & Francis in Platelets
- Vol. 34 (1) , 2222184
Abstract
Although the presence of glycogen in platelets was established in the 1960s, its importance to specific functions (i.e., activation, secretion, aggregation, and clot contraction) remains unclear. Patients with glycogen storage disease often present with increased bleeding and glycogen phosphorylase (GP) inhibitors, when used as treatments for diabetes, induce bleeding in preclinical studies suggesting some role for this form of glucose in hemostasis. In the present work, we examined how glycogen mobilization affects platelet function using GP inhibitors (CP316819 and CP91149) and a battery of ex vivo assays. Blocking GP activity increased glycogen levels in resting and thrombin-activated platelets and inhibited platelet secretion and clot contraction, with minimal effects on aggregation. Seahorse energy flux analysis and metabolite supplementation experiments suggested that glycogen is an important metabolic fuel whose role is affected by platelet activation and the availability of external glucose and other metabolic fuels. Our data shed light on the bleeding diathesis in glycogen storage disease patients and offer insights into the potential effects of hyperglycemia on platelets.Keywords
Funding Information
- NIH, NHLBI
- Department of Veterans Affairs Merit Award
This publication has 24 references indexed in Scilit:
- Glycogen metabolism has a key role in the cancer microenvironment and provides new targets for cancer therapyJournal of Molecular Medicine, 2016
- Investigation and management of the hepatic glycogen storage diseases2015
- Metabolic Plasticity in Resting and Thrombin Activated PlateletsPLOS ONE, 2015
- A review of the mitochondrial and glycolytic metabolism in human platelets and leukocytes: Implications for their use as bioenergetic biomarkersRedox Biology, 2014
- Menorrhagia in Patients With Type I Glycogen Storage DiseaseObstetrics & Gynecology, 2013
- Prolonged Inhibition of Glycogen Phosphorylase in Livers of Zucker Diabetic Fatty Rats Models Human Glycogen Storage DiseasesToxicologic Pathology, 2010
- Astrocyte Glycogen Sustains Neuronal Activity during Hypoglycemia: Studies with the Glycogen Phosphorylase Inhibitor CP-316,819 ([R-R*,S*]-5-Chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl)propyl]-1 H-indole-2-carboxamide)The Journal of Pharmacology and Experimental Therapeutics, 2007
- Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type IaJournal of Inherited Metabolic Disease, 2005
- Glycogen Phosphorylase Inhibition in Type 2 Diabetes TherapyDiabetes, 2005
- THE HEMOSTATIC DEFECT IN GLYCOGEN STORAGE DISEASE, TYPE IActa Paediatrica, 1968